J. Fiore

发表

A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers

C. Rudin, M. Kris, P. Paik, 2020, Clinical Cancer Research.

Phase II Study of a Non‐Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas

A. Lash, L. Schwartz, M. Kris, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

C. Sima, M. Kris, C. Azzoli, 2012, Clinical Cancer Research.

Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

M. Kris, C. Azzoli, Gregory Riely, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.

M. Kris, R. Gralla, R. Heelan, 1986, Cancer treatment reports.

Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.

M. Viola, H. Malhotra, R. Caruso, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment.

M. Kris, E. Casper, R. Gralla, 1985, Chest.

Normal G2 chromosomal radiosensitivity and cell survival in the cancer family syndrome.

M. Bender, M. Viola, J. Fiore, 1988, Cancer research.

Actual 5-year survival of patients with stage IIIB breast carcinoma: phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid.

D. Matei, A. Kudelka, L. Pendyala, 1999, Cancer investigation.

Metastatic Adenocarcinomas of Unknown Primary Site: Prognostic Variables and Treatment Results

D. Niedzwiecki, V. Vinciguerra, D. Kelsen, 1990, American journal of clinical oncology.

Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin.

E. Casper, R. Gralla, D. Kelsen, 1985, Cancer treatment reports.

Proteinase‐alpha2 macroglobulin complexes are not increased in plasma of patients with cancer

D. Strickland, S. Zucker, R. Lysik, 1991, International journal of cancer.

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

David R. Jones, N. Schultz, M. Ladanyi, 2021, Nature Medicine.

Pharmacologic treatment of chemotherapy-induced nausea and vomiting.

R. Gralla, J. Fiore, 1984, Cancer investigation.

A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.

C. Sima, M. Kris, Gregory Riely, 2015 .

Systemic absorption of a leucovorin mouth wash: a pharmacologic study.

N. Geller, N. Kemeny, J. Fiore, 1987, Cancer investigation.

Significance of Oncogenes in Breast Cancer: Review

M. Viola, J. Fiore, 1989 .

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

C. Sima, C. Rudin, M. Kris, 2016, Clinical lung cancer.

Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.

S. Groshen, M. Kris, S. Groshen, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protein A immunoadsorption in the treatment of malignant disease.

M. Viola, D. Henry, A. Mittelman, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimal toxicity during protein a immunoadsorption treatment of malignant disease: An outpatient therapy

John Fiore, L. Fisher, M. Viola, 1991, Journal of clinical apheresis.

Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.

S. Groshen, M. Kris, R. Gralla, 1985, Cancer treatment reports.

Clinical experience with 5-FU/DDP +/- OHDW combination chemotherapy in patients with advanced colorectal carcinoma.

S. Madajewicz, J. Fiore, M. Zarrabi, 1988, Advances in experimental medicine and biology.

Phase II trial of oral 4‐demethoxydaunorubicin in patients with non‐small cell lung cancer

M. Kris, J. Fiore, M. Burke, 1985, American Journal of Clinical Oncology.

Phase II trial of esorubicin in patients with advanced non-small cell lung cancer.

M. Kris, R. Gralla, R. Heelan, 1987, Cancer treatment reports.

Preclinical and clinical evaluation of 5‐fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma

H. Zarrabi, P. Hentschel, J. Fiore, 1995, Cancer.

Phase I C hemotherapy S tudy o f B iochemical M odulation o f Folinic A cid a nd F luorouracil b y G emcitabine i n P atients With S olid T umor M alignancies

M. Viola, H. Malhotra, R. Caruso, 2000 .

Protein A immunotherapy in the treatment of cancer: an update.

M. Viola, A. Mittelman, S. Ainsworth, 1989, Seminars in hematology (Print).

Phase II Study of a Non-platinum-containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab (PPB) as Initial Therapy for Patients with Advanced Lung Adenocarcinomas

M. Kris, M. Hellmann, C. Pietanza, 2016 .

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

David R. Jones, N. Schultz, M. Ladanyi, 2022, Nature Medicine.